Publication
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Journal Paper/Review - Oct 26, 2021
Schmiedeberg Kristin, Vuilleumier Nicolas, Pagano Sabrina, Albrich Werner, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Units
Rheumatologie, Division of Infectious Diseases, Infection Prevention and Travel Medicine, Medizinisches Forschungszentrum, Institute of Immunobiology
PubMed
Doi
Citation
Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatol 2021; 4:e11-e13.
Type
Journal Paper/Review (English)
Journal
Lancet Rheumatol 2021; 4
Publication Date
Oct 26, 2021
Issn Electronic
2665-9913
Pages
e11-e13